Skip to main content

Acute Bacterial Conjunctivitis

6
Pipeline Programs
3
Companies
3
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
4
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 3 programs with unclassified modality

On Market (1)

Approved therapies currently available

Bausch + Lomb
BESIVANCEApproved
besifloxacin
Bausch + Lomb
Quinolone Antimicrobial [EPC]ophthalmic2009
11M Part D

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Bausch + Lomb
Bausch + LombNJ - Bridgewater
2 programs
2
1
BesifloxacinPhase 3Small Molecule
ISV-403Phase 3
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
2 programs
2
BesifloxacinPhase 3Small Molecule1 trial
ISV-403Phase 31 trial
Active Trials
NCT00348348Completed1,161Est. Jul 2007
NCT00347932Completed957Est. Nov 2007
IVIEW Therapeutics
IVIEW TherapeuticsNJ - Cranbury
1 program
1
IVIEW-1201Phase 21 trial
Active Trials
NCT05816070Completed129Est. Oct 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bausch HealthBesifloxacin
Bausch HealthISV-403
IVIEW TherapeuticsIVIEW-1201

Clinical Trials (3)

Total enrollment: 2,247 patients across 3 trials

NCT00348348Bausch HealthBesifloxacin

A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis

Start: Jun 2006Est. completion: Jul 20071,161 patients
Phase 3Completed
NCT00347932Bausch HealthISV-403

A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.

Start: Jun 2006Est. completion: Nov 2007957 patients
Phase 3Completed
NCT05816070IVIEW TherapeuticsIVIEW-1201

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis

Start: Jan 2023Est. completion: Oct 2024129 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.